Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IXKOE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RFB4-SMPT-dgA
|
|||||
| Synonyms |
Anti-CD22 monoclonal antibody RFB4-ricin chain A conjugate; IgG-RFB4-SMPT-dgA; Monoclonal antibody RFB4-ricin chain A conjugate; NSC 639179; NSC639179; RFB4-SMPT-dgA
Click to Show/Hide
|
|||||
| Organization |
National Cancer Institute; The University of Texas Southwestern Medical Center
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
RFB4
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Deglycosylated ricin A-chain (dgA)
|
Payload Info | ||||
| Linker Name |
Succynimidyloxycarbonyl-alpha-methyl-alpha- (2-pyridyl-dithio) toluene (SMPT)
|
Linker Info | ||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma |
1 Trials
|
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 93 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 12.9 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 1.
|
[1] |
| Maximum Observed Concentration (Cmax) | 63 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 2.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 2.
|
[1] |
| Maximum Observed Concentration (Cmax) | 69 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 4.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 9.1 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 4.
|
[1] |
| Maximum Observed Concentration (Cmax) | 75±16 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Avg SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 8.7±4.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Avg SD.
|
[1] |
| Maximum Observed Concentration (Cmax) | 398 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 55.7 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 3.
|
[1] |
| Maximum Observed Concentration (Cmax) | 326 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 5.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 32.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 5.
|
[1] |
| Maximum Observed Concentration (Cmax) | 604 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 6.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 82.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 6.
|
[1] |
| Maximum Observed Concentration (Cmax) | 443±144 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, AVG SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 56.9±25.1 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, AVG SD.
|
[1] |
| Maximum Observed Concentration (Cmax) | 88 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 7.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 9.4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 7.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1572 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 8.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 224.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 8.
|
[1] |
| Maximum Observed Concentration (Cmax) | 9.6 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 10.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 10.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1272 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 11.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 164.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 11.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1792 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 12.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 117.9 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 12.
|
[1] |
| Maximum Observed Concentration (Cmax) | 460 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 13.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 66.7 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 13.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1253 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 14.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 164.4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 14.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1079 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 15.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 72.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 15.
|
[1] |
| Maximum Observed Concentration (Cmax) | 728 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 16.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 107.8 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 16.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1032 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 17.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 114.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 17.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1837 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 18.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 118.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 18.
|
[1] |
| Maximum Observed Concentration (Cmax) | 1102±702 | ng/mL |
Peak serum concentration, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, AVG SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 105.6±66.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, AVG SD.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Volume of Distribution (Vd) | 18.5 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 12.9 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 1.
|
[1] |
| Volume of Distribution (Vd) | 15.5 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 2.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 2.
|
[1] |
| Volume of Distribution (Vd) | 23.6 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 4.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 9.1 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 4.
|
[1] |
| Volume of Distribution (Vd) | 19.2±4.1 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Avg SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 8.7±4.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Avg SD.
|
[1] |
| Volume of Distribution (Vd) | 8.9 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 55.7 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 3.
|
[1] |
| Volume of Distribution (Vd) | 19.5±3.7 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 5.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 32.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 5.
|
[1] |
| Volume of Distribution (Vd) | 7.6 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 6.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 82.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 6.
|
[1] |
| Volume of Distribution (Vd) | 12±6.5 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, AVG SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 56.9±25.1 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, AVG SD.
|
[1] |
| Volume of Distribution (Vd) | 23.8 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 7.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 9.4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 7.
|
[1] |
| Volume of Distribution (Vd) | 8.6 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 8.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 224.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 8.
|
[1] |
| Volume of Distribution (Vd) | 660.9 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 10.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 10.
|
[1] |
| Volume of Distribution (Vd) | 5.4 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 11.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 164.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 11.
|
[1] |
| Volume of Distribution (Vd) | 3.5 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 12.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 117.9 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 12.
|
[1] |
| Volume of Distribution (Vd) | 5.6 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 13.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 66.7 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 13.
|
[1] |
| Volume of Distribution (Vd) | 6.8 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 14.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 164.4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 14.
|
[1] |
| Volume of Distribution (Vd) | 9.2 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 15.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 72.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 15.
|
[1] |
| Volume of Distribution (Vd) | 4.4 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 16.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 107.8 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 16.
|
[1] |
| Volume of Distribution (Vd) | 1.3 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 17.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 114.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 17.
|
[1] |
| Volume of Distribution (Vd) | 3.3 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 18.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 118.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 18.
|
[1] |
| Volume of Distribution (Vd) | 66.6±197.2 | L |
Volume of distribution, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, AVG SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 105.6±66.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, AVG SD.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 12.9 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 2.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 9.1 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 4.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 8.7±4.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Avg SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 55.7 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 32.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 5.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 82.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 6.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 56.9±25.1 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, AVG SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 9.4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 7.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 224.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 8.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 10.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 164.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 11.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 117.9 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 12.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 66.7 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 13.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 164.4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 14.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 72.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 15.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 107.8 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 16.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 114.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 17.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 118.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 18.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 105.6±66.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, AVG SD.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 9.4 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 12.9 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 1.
|
[1] |
| Clearance (CL) | 1.4 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 1.
|
[1] |
| Elimination Half-Life (t1/2) | 3.3 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 2.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 2.
|
[1] |
| Clearance (CL) | 3.3 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 2.
|
[1] |
| Elimination Half-Life (t1/2) | 7.7 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 4.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 9.1 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 4.
|
[1] |
| Clearance (CL) | 2.1 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Patient 4.
|
[1] |
| Elimination Half-Life (t1/2) | 6.8±3.1 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Avg SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 8.7±4.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Avg SD.
|
[1] |
| Clearance (CL) | 2.3±0.9 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 1, 9.6 mg/m2/196h, Avg SD.
|
[1] |
| Elimination Half-Life (t1/2) | 9.1 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 55.7 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 3.
|
[1] |
| Clearance (CL) | 0.68 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 3.
|
[1] |
| Elimination Half-Life (t1/2) | 13 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 5.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 32.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 5.
|
[1] |
| Clearance (CL) | 1 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 5.
|
[1] |
| Elimination Half-Life (t1/2) | 14.1 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 6.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 82.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 6.
|
[1] |
| Clearance (CL) | 0.37 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, Patient 6.
|
[1] |
| Elimination Half-Life (t1/2) | 12.1±2.6 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, AVG SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 56.9±25.1 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, AVG SD.
|
[1] |
| Clearance (CL) | 0.68±0.31 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 2, 19.2 mg/m2/196h, AVG SD.
|
[1] |
| Elimination Half-Life (t1/2) | 2.6 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 7.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 9.4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 7.
|
[1] |
| Clearance (CL) | 6.3 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 7.
|
[1] |
| Elimination Half-Life (t1/2) | 23.14±3.5 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 8.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 224.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 8.
|
[1] |
| Clearance (CL) | 0.26 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 8.
|
[1] |
| Elimination Half-Life (t1/2) | 8.9 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 10.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 10.
|
[1] |
| Clearance (CL) | 51.2 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 10.
|
[1] |
| Elimination Half-Life (t1/2) | 10.6 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 11.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 164.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 11.
|
[1] |
| Clearance (CL) | 0.36 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 11.
|
[1] |
| Elimination Half-Life (t1/2) | 10.1 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 12.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 117.9 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 12.
|
[1] |
| Clearance (CL) | 0.24±0.22 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 12.
|
[1] |
| Elimination Half-Life (t1/2) | 5.2 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 13.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 66.7 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 13.
|
[1] |
| Clearance (CL) | 0.75 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 13.
|
[1] |
| Elimination Half-Life (t1/2) | 18.2 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 14.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 164.4 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 14.
|
[1] |
| Clearance (CL) | 0.26 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 14.
|
[1] |
| Elimination Half-Life (t1/2) | 20.1±15.5 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 15.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 72.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 15.
|
[1] |
| Clearance (CL) | 0.32 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 15.
|
[1] |
| Elimination Half-Life (t1/2) | 5.3 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 16.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 107.8 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 16.
|
[1] |
| Clearance (CL) | 0.57 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 16.
|
[1] |
| Elimination Half-Life (t1/2) | 6 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 17.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 114.2 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 17.
|
[1] |
| Clearance (CL) | 0.15 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 17.
|
[1] |
| Elimination Half-Life (t1/2) | 15.7 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 18.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 118.6 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 18.
|
[1] |
| Clearance (CL) | 0.14 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, Patient 18.
|
[1] |
| Elimination Half-Life (t1/2) | 11.4±6.8 | h |
Elimination half-life, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, AVG SD.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 105.6±66.5 | mg*h/L |
Area under the concentration versus time curve, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, AVG SD.
|
[1] |
| Clearance (CL) | 5.5±15.3 | L/h |
Clearance, Pharmacokinetic Parameters With Continuous Infusion lgG-RFB4-SMPT-dgA, Level 3, 28.8 mg/m2/196h, AVG SD.
|
[1] |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible patients must have CD22+ (≥30%) B-cell NHL (excluding CLL, ALL, and hairy cell leukemia), measurable disease (excluding marrow-only involvement), and progression post-chemotherapy, with adequate organ function (CrCl >60 mL/min, bilirubin <1.5 mg/dL, EF ≥35% if prior doxorubicin).Key exclusions include HIV, CNS/pulmonary involvement, recent chemotherapy (<2 weeks), and transplant candidates. Required labs: SGPT <2x ULN, albumin >75% LLN, PS 0-2, and life expectancy ≥3 months.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00001271 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma | ||||
References